X-linked agammaglobulinemia is a primary immunodeficiency disorder resulting from BTK gene mutations. There are many studies in the literature suggesting contradictory ideas about phenotype-genotype correlation. The aim of this study was to identify the mutations and clinical findings of patients with XLA in Turkey, to determine long-term complications related to the disease and to analyse the phenotype-genotype correlation. Thirty-two patients with XLA diagnosed between 1985 and 2016 in Pediatric Immunology Department of Hacettepe University Ihsan Dogramaci Children's Hospital were investigated. A clinical survey including clinical features of the patients was completed, and thirty-two patients from 26 different families were included in the study. Getting early diagnosis and regular assessment with imaging techniques seem to be the most important issues for improving the health status of the patients with XLA. Early molecular analysis gives chance for definitive diagnosis and genetic counselling, but not for predicting the clinical severity and prognosis.
| INTRODUCTION
X-linked agammaglobulinemia (XLA, OMIM# 300755) was first described in 1952 by Bruton, 1 and the responsible gene, Bruton's tyrosine kinase (BTK), was identified in 1993. 2, 3 The defective BTK gene causes impairment of Bcell differentiation resulting in absence or low number of B cells in peripheral blood, profound hypogammaglobulinemia and disruption of specific antibody production. 4 Lifetime immunoglobulin replacement therapy is required to diminish the infection and infection-associated complications. 5 Most commonly seen infections are upper respiratory tract infections, pneumonia, diarrhoea (mostly caused by Giardia lamblia) and skin infections. Although there is enough protection against viruses and fungi, enteroviruses are an exception and may cause severe meningoencephalitis.
tions in the first 5 years of life, serum immunoglobulin levels more than 2SD below normal for age, CD19+ B cells <2%, absence of isohemagglutinins and poor vaccine response made us give a probable diagnosis of XLA whereas defined BTK mutation was needed for a definite diagnosis as in our patient group. We completed a clinical survey including the age at which symptoms started, age at diagnosis, types of infections, family history of XLA, treatment and complications, presence of malnutrition, levels of IgG in the first and last year of intravenous immunoglobulin (IVIg) replacement. The age at which the patient is diagnosed to have agammaglobulinemia and started IVIg replacement (not the age at which mutation was confirmed) was noted as the age at diagnosis.
The study was approved by the Hacettepe University Ethics Committee. Informed consent form was obtained from patients and families.
| Methods

| Molecular analysis
DNA was isolated from peripheral blood granulocytes after separation using Ficoll-Paque (GE Healthcare, Little Chalfont, UK) according to the manufacturer's instructions. Sequence analysis of BTK was performed following PCR amplification of the coding regions with TaqGold TM (Life Technologies), followed by direct sequencing on an ABI Prism 3130 XL fluorescent sequencer (Applied Biosystems, Bleiswijk, the Netherlands). Primer sequences are available upon request. Sequences were compared to the NCBI reference sequence (958957).
| Statistical analysis
We used descriptive statistics to define the demographical and immunological data and clinical characteristics.
Wilcoxon rank-sum test or Fisher's exact test was used to analyse the differences in percentages of categorical variables. Student's t test was used to compare means of continuous variables. The Spearman's correlation tests were used for the correlation of the parameters. All P values are two-sided, and values <.05 were considered statistically significant. The SPSS 22.0 was used for analysis of the data.
| RESULTS
| Patient characteristics and clinical manifestations
Thirty-two patients from 26 different families were included in the study (Table 1) . Median age of patients during study was 14.3 years (0.91-33). Median age at onset of symptoms was 9.5 months (7.0-108), and median age at diagnosis was 3.5 years (0. . Family history for XLA was positive in 15 patients (47%). Median age at diagnosis and time of diagnosis from disease onset in patients with and without positive family history of XLA were 2.08 years (0.25-6) vs 4.66 years(0.91-14) and 1.25 years (0-4.83) vs 2.08 years (0.16-13.33), respectively ( Table 2) . The difference was statistically significant (P < .005).
We know that the new information about the disease over time allows both the patients to be diagnosed earlier and the necessary treatment to be reached sooner. For this purpose, the patients were divided into two according to the year of birth and evaluated before and after 1995. The reason for choosing 1995 as a cut-off point was to be in the middle of the patient collection period, which was determined as 1980-2016. Twelve patients (37.5%) were in the first group. The median age at diagnosis of the former (older) group was 4.66 years (0.75-11.69), and the latter (younger) was 2.00 years (0. . The median time of diagnosis from disease onset in former and the latter groups were 2.66 years (0. 16-10. Other clinical manifestations and complications during follow-up were encephalopathy (P10, P14, P23, P29), vaccine-associated paralytic poliomyelitis(VAPP) (P6), autoimmunity [Guillain-Barre syndrome (P4)], juvenile idiopathic arthritis (P13), polyarthritis nodosa (P23), chronic atrophic gastritis (P27), Crohn's disease (P27)], malignancy[nonHodgkin lymphoma, died at 14 years of age (P5)], neutropenia (P15, P16, P32), 7 of the patients were evaluated with chest computed tomography (CT); 6 of them had radiographic evidence of bronchiectasis (P8, P11, P13, P22, P25, P27). Six (19%) of the patients were malnourished, whereas 3 (9%) of them were obese.
P6 who was diagnosed with vaccine-associated poliomyelitis at the age of 11 months had no symptom until 7 months of age. He was treated for tonsillitis and bronchiolitis after 7 months of age and was admitted to hospital for progressive loss in the ability of walking and head control, then cough reflex; and drowsiness. Microbiology of CSF was negative for EBV, mycoplasma pneumonia, HSV 1-2, varicella and bacteria. The spinal MRI was compatible with myelitis. Stool examination revealed vaccine-related polio infection (poliovirus type 2 was Time of diagnosis from disease onset (years)* 
| BTK mutations
Different types of BTK gene mutations were detected in 26 families. The mutations and affected BTK gene domains are shown in Table 3 and Figure 1 .
| DISCUSSION
This study evaluates the clinical, immunological and genetic characteristics of 32 Turkish patients with XLA. In this study, all the patients fulfilled the clinical diagnostic criteria for XLA and had BTK mutations. There are separate studies on 6 and 16 Turkish patients with XLA in 1990 15 and in 2001, 16 and the present study is the largest patient series from Turkey, a developing country, in the literature. The age at the onset of symptoms, age at diagnosis and time of diagnosis from disease onset were analysed. The median age at diagnosis was 3.5 years (0. which was found to be 7 years (0.9-19) in the Chinese cohort 17 and 3 years (0. in the Italian multicentre study. 18 Factors affecting the age at diagnosis and time of diagnosis from disease onset were found to be positive family history and year of birth (closer to the day or from 20 years ago) which was compatible with the literature. 17, 18 In the present study, patients who had positive family history of XLA might be evaluated earlier and with the time passing the awareness regarding primary immunodeficiencies is increasing as expected. Two of our patients with positive family history were diagnosed before the symptoms started.
Upper and lower respiratory tract infections and acute episodes of diarrhoea were the most common infections recorded in our patients before diagnosis. Despite IVIg replacement therapy, patients are not infection free, retain a higher than average susceptibility to these type of mucosal infections, which may possibly due to inadequate activity of IgG on mucosal surfaces, with a decrease in number and severity. Since Turkey is a developing country, ongoing infections may be related to the crowded house conditions and sociocultural situation also. The findings are similar to other studies [18] [19] [20] [21] suggesting the prime importance of early diagnosis and early initiation of IVIg replacement therapy in order to diminish the frequency and severity of the especially lower respiratory tract infections (LTRI) and its complications like bronchiectasis. Since pulmonary complications are the main cause of death in case of antibody deficiencies, it is necessary to regularly evaluate the patients with pulmonary function tests and imaging techniques such as HRCT. In our study, only 7 of the patients were evaluated with chest CT and 6 of them had bronchiectasis. In the Italian multicentre study, 15 patients (38.5%) had already developed chronic lung disease at the time of diagnosis and the mean age at diagnosis was found to be higher in those patients than the patients without chronic lung disease at diagnosis (7.8 years vs 4.8 years). 18 Even patients who do not have any complaints should be evaluated with chest CT. If we had performed chest CT as a routine technique at least during diagnosis and in the follow-up, more patients would get earlier diagnosis of bronchiectasis and the modification in their therapy (optimization in the IVIg replacement frequency and dose, antimicrobial prophylaxis, chest physiotherapy) would be done in order to prevent further progression.
Encephalitis was another rather commonly seen complication of XLA which was thought to be mostly caused by enteroviruses. Four of our patients suffered from encephalitis with no proven microbiological agent. The agents isolated in 2 of our patient were H. influenza and S. pneumonia. The encephalitis and meningitis are severe infections in patients with XLA with a chronic and systemic course. 22 None of the patients suffered meningitis or encephalitis after IVIg replacement therapy. One of our patients got the diagnosis with VAPP. According to our national vaccination policy, the patient was vaccinated with inactivated polio vaccine at 2, 4 and 6 months of age and live oral polio vaccine at 6 months of age. VAPP has been reported in 2 patients among 62 Chinese XLA patients, 17 2 patients among 73 Italian patients with XLA 18 and 2 patients in the US cohort. 23 The mutation of the patient was c. 142-1G>T, and it was different from the case presented in the literature c.685_686ins TTAC. 24 In order to minimize the occurrence of this serious complication, a detailed family history regarding XLA should be asked before routine vaccination. In our study, one of our patients died because of nonHodgkin lymphoma. The actual incidence of malignancies in XLA is not defined yet but the prevalence of any malignancy in XLA has been estimated to be between 1.5% and 6%. 25 There are case reports about the XLA and some malignancies like acute lymphoblastic leukaemia (ALL), lymphoma, gastric adenocarcinoma, colorectal cancer. 26, 27 The authors claim that cancer in BTK-deficient patients is most probably a late complication attributable to chronic infection. And with the management of infections, prognosis for XLA patients improve, more of the patients will reach adolescence and adulthood with increased risk of malignancy. 27 The median IgG level in the last year of follow-up was 687 mg/dL in our patients. However, residual IgG levels >500 mg/dL have generally considered to be protective, the recent findings indicate that the threshold of 500 mg/ dL may be insufficient and >800 mg/dL compared to >500 mg/dL ensures significantly lower incidence of serious bacterial infections. 20 For protection from lung complications, the IVIg doses should be increased in order to maintain serum IgG level >800 mg/dL and antimicrobial prophylaxis with regular chest physiotherapy should be started. 18 A recent study on respiratory health and related quality of life in patients with congenital agammaglobulinemia showed a significant burden of respiratory disease on a patient's life. 28 From 26 different families, 26 different mutations were detected. Mutations that we identified in our patients had a similar distribution pattern to the mutations in the BTKbase. 29 showed correlation between genotype and disease onset and occurrence of severe infections. Since we did not performed any functional study regarding the BTK protein (structure or quantity), we could not give information about phenotype-genotype correlation. In case of early diagnosis and initiation of appropriate treatment, the prognosis of XLA is generally good. Despite IVIg replacement, patients still suffer from URTI, pneumonia or diarrhoea. Patients should be evaluated regularly with imaging techniques to diagnose pulmonary complications early, and IVIg doses should be optimized when necessary. Subcutaneous Ig replacement therapy should be kept in mind as an alternative method with many advantages.
Getting early diagnosis and regular assessment with imaging techniques seems to be the most important issues for improving the health status of the patients with XLA.
Early molecular analysis gives chance for definitive diagnosis and genetic counselling, but not for predicting the clinical severity and prognosis.
